ShumeiKatoMD

PubMed

• High indoleamine 2,3-dioxygenase transcript levels predict better outcome after front-line cancer immunotherapy.
  Daisuke Nishizaki, Suzanna Lee, Mary K Nesline, Jeffrey M Conroy, Paul DePietro, Sarabjot Pabla, Yu Fujiwara, Shumei Kato, Hirotaka Miyashita, Scott M Lippman, Razelle...> ;Iscience. 2024 Apr 19
• A Phase 1 Study of KIN-3248, an irreversible small molecule pan-FGFR inhibitor, in Patients with Advanced FGFR 2/3 Driven Solid Tumors.
  Harding, J., Rastislav Bahleda, Cesar A Perez, Li-Tzong Chen, Do-Youn Oh, Paul Severson, Betty Y Tam, Benjamin Garmezy, Mitesh J Borad, Shumei Kato, Cheng Quah, James ...> ;Cancer Research Communications. 2024 Apr 11
• 1 citations
  Evolution of Precision Oncology, Personalized Medicine, and Molecular Tumor Boards.
  Yu Fujiwara, Shumei Kato, Razelle Kurzrock> ;Surgical Oncology Clinics of North America. 2024 Apr 1
• OX40/OX40 ligand and its role in precision immune oncology.
  Daisuke Nishizaki, Suzanna Lee, Mary K Nesline, Rebecca A Previs, Jeffery M Conroy, Paul DePietro, Sarabjot Pabla, Bicky Thapa, Shumei Kato, Hirotaka Miyashita, Razell...> ;Cancer Metastasis Reviews. 2024 Mar 25
• If it's a target, it's a pan-cancer target: Tissue is not the issue.
  Jacob J Adashek, Shumei Kato, Jason K Sicklick, Scott M Lippman, Razelle Kurzrock> ;Cancer Treatment Reviews. 2024 Apr 1
• Neuregulin-1 and ALS19 (ERBB4): at the crossroads of amyotrophic lateral sclerosis and cancer.
  Jacob J Adashek, Chinmayi Pandya, Nicholas J Maragakis, Pradip De, Philip R Cohen, Shumei Kato, Razelle Kurzrock> ;BMC Medicine. 2024 Feb 19
• High CTLA-4 transcriptomic expression correlates with high expression of other checkpoints and with immunotherapy outcome.
  Krishnamurthy, N., Nishizaki, D., Nesline, M., Pabla, S., Conroy, J., DePietro, P., Lippman, S., Miyashita, H., Kato, S., Kurzrock, R.> ;Therapeutic Advances in Medical Oncology. 2024 Jan 1
• LAG-3 transcriptomic expression correlates linearly with other checkpoints, but not with clinical outcomes.
  Nishizaki, D., Pabla, S., Nesline, M., Previs, R., Conroy, J., DePietro, P., Kurzrock, R., Adashek, J., Kato, S.> ;American Journal of Cancer Research. 2024 Jan 1
• Pan-cancer analysis of TIM-3 transcriptomic expression reveals high levels in pancreatic cancer and interpatient heterogeneity.
  Lim, J., Nishizaki, D., Lee, S., Pabla, S., Nesline, M., Conroy, J., DePietro, P., Kurzrock, R., Miyashita, H., Adashek, J., Lippman, S., Kato, S.> ;Cancer Medicine. 2023 Dec 22
• 2 citations
  Considering molecular alterations as pan-cancer tissue-agnostic targets.
  Jacob J Adashek, Shumei Kato, Jason K Sicklick, Scott M Lippman, Razelle Kurzrock> ;Nature Cancer. 2023 Dec 1
• 6 citations
  ALK fusions in the pan-cancer setting: another tumor-agnostic target?
  Aditya Shreenivas, Filip Janku, Mohamed A Gouda, Hui-Zi Chen, Ben George, Shumei Kato, Razelle Kurzrock> ;NPJ Precision Oncology. 2023 Sep 29
• At the right dose: personalised (N-of-1) dosing for precision oncology.
  Mina Nikanjam, Shumei Kato, Jason K Sicklick, Razelle Kurzrock> ;European Journal of Cancer. 2023 Nov 1
• Cancer-Immunity Marker RNA Expression Levels across Gynecologic Cancers: Implications for Immunotherapy.
  Jessica Jou, Shumei Kato, Hirotaka Miyashita, Kartheeswaran Thangathurai, Sarabjot Pabla, Paul DePietro, Mary K Nesline, Jeffrey M Conroy, Eitan Rubin, Ramez N Eskande...> ;Molecular Cancer Therapeutics. 2023 Nov 1
• 1 citations
  T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapy.
  Hirotaka Miyashita, Razelle Kurzrock, Nicholas J Bevins, Kartheeswaran Thangathurai, Suzanna Lee, Sarabjot Pabla, Mary Nesline, Sean T Glenn, Jeffrey M Conroy, Paul De...> ;NPJ Genomic Medicine. 2023 Aug 8
• 2 citations
  Comprehensive Analysis of Human Epidermal Growth Factor Receptor 2 Through DNA, mRNA, and Protein in Diverse Malignancies.
  Akram Mesleh Shayeb, Razelle Kurzrock, Jacob J Adashek, Shumei Kato> ;JCO Precision Oncology. 2023 Jul 1
• 5 citations
  LAG-3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics.
  Jacob J Adashek, Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Pradip De, Suzanna Lee, Sarabjot Pabla, Mary Nesline, Jeffrey M Conroy, Paul DePietro, Scott Lippm...> ;Cancer Medicine. 2023 Jun 1
• 11 citations
  Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study.
  Filippo de Braud, Christophe Dooms, Rebecca S Heist, Celeste Lebbe, Martin Wermke, Anas Gazzah, Dirk Schadendorf, Piotr Rutkowski, Jürgen Wolf, Paolo A Ascierto, Ignac...> ;Journal of Clinical Oncology. 2023 May 10
• 3 citations
  BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study.
  Blessie Elizabeth Nelson, Jason Roszik, Filip Janku, David S Hong, Shumei Kato, Aung Naing, Sarina Piha-Paul, Siqing Fu, Apostolia Tsimberidou, Maria Cabanillas, Naifa...> ;NPJ Precision Oncology. 2023 Feb 18
• Cancer immunity marker RNA expression levels across gynecologic cancers: Implications for immunotherapy.
  Jessica Jou, Shumei Kato, Hirotaka Miyashita, Kartheeswaran Thangathurai, Sarabjot Pabla, Paul DePietro, Mary Nesline, Jeffrey Conroy, Eitan Rubin, Ramez Eskander, Raz...> ;Research Square. 2023 Feb 16
• 2 citations
  Dosing of 3 Targeted Agents in Novel Drug Combinations Used at the Precision Medicine Clinic of the University of California San Diego.
  Mina Nikanjam, Jose Tinajero, Mary McGann, Jerry Li, Jincheng Yang, Felicity Shen, Jason K Sicklick, Shumei Kato, Edmund Capparelli, Razelle Kurzrock> ;Journal of Hematology Oncology Pharmacy. 2023 Feb 1
• Concordance between cancer gene alterations in tumor and circulating tumor DNA correlates with poor survival in a real-world precision-medicine population.
  Shai Rosenberg, Gil Ben Cohen, Shumei Kato, Ryosuke Okamura, Scott M Lippman, Razelle Kurzrock> ;Molecular Oncology. 2023 Sep 1
• 13 citations
  Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis.
  Justin Shaya, Shumei Kato, Jacob J Adashek, Hitendra Patel, Paul T Fanta, Gregory P Botta, Jason K Sicklick, Razelle Kurzrock> ;NPJ Genomic Medicine. 2023 Jan 20
• 1 citations
  Challenges and prospects of CSF1R targeting for advanced malignancies.
  Ann Moeller, Razelle Kurzrock, Gregory P Botta, Jacob J Adashek, Hitendra Patel, Suzanna Lee, Sarabjot Pabla, Mary K Nesline, Jeffrey Conroy, Jason K Sicklick, Shumei ...> ;American Journal of Cancer Research. 2023 Jan 1
• 7 citations
  Targeting the FGF/FGFR axis and its co-alteration allies.
  Y Uehara, S Ikeda, K H Kim, H J Lim, J J Adashek, H E Persha, R Okamura, S Lee, J K Sicklick, S Kato, R Kurzrock> ;ESMO Open. 2022 Dec 1
• 2 citations
  Detection of microsatellite instability high (MSI-H) status by targeted plasma-based genotyping in metastatic breast cancer.
  Neelima Vidula, Andrew Lipman, Shumei Kato, Caroline Weipert, Katherine Hesler, Georges Azzi, Ahmed Elkhanany, Dejan Juric, Estelamari Rodriguez, Colleen Faulkner, Pau...> ;NPJ Breast Cancer. 2022 Nov 4
• Join now to see all

Journal Articles

• Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction and Gastric Adenocarcinoma  
  Lawrence Leichman, Jason K Sicklick, Shumei Kato, Kaitlyn Kelly, Scott M Lippman, Clinical Cancer Research

Lectures

• A functional measurement of MAPK pathway activation to predict response to MEK inhibitors in RAS-mutated patients. 
  2019 ASCO Annual Meeting - 6/1/2019
• PDL1 landscape in checkpoint inhibitor ineligible patients by IHC and cfRNA. 
  2019 ASCO Annual Meeting - 6/1/2019
• RAS alterations: Next-generation sequencing of 1,526 patients with diverse malignancies reveals prognostic and therapeutic correlates. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018